Ipamorelin Regulatory Status: Compounding Access in 2026
A plain-language look at where ipamorelin sits with the FDA, and what Category 2 means for access.
TL;DR
Ipamorelin regulatory status in 2026 is Category 2. That means the FDA (Food and Drug Administration) has flagged it, and 503A compounding pharmacies cannot compound it while that status holds. Ipamorelin is not FDA-approved, and no compounded version is FDA-approved. A 2026 proposal could change this, but only after a formal notice.
What ipamorelin regulatory status means today
Ipamorelin regulatory status today is "Category 2," which restricts compounding access. The FDA sorts nominated bulk substances into categories. Category 2 is the flagged bucket: the agency has significant questions about compounding it from raw powder. The FDA placed ipamorelin in Category 2 during its review of nominated bulk substances (FDA, 2023). While that stands, a compliant 503A pharmacy (a state-licensed pharmacy that makes patient-specific medicines) should not compound it.
How the category system works
The category system is the FDA's way of deciding what compounding pharmacies may use. Think of it like a guest list at a door. Category 1 substances may go in; Category 2 substances are held back pending review. Ipamorelin is on the held-back list. That is a compounding-access decision, not a criminal ban on the molecule itself.
Who asks about this
People considering growth hormone secretagogue peptides ask about ipamorelin's status most often. A growth hormone secretagogue (in plain English: a compound studied for prompting the body's own growth hormone release) draws interest, but interest does not equal access. The regulatory answer comes before any clinical conversation.
What could change
The access picture could shift, but nothing has changed yet. A February 2026 HHS (Department of Health and Human Services) announcement proposed returning several Category 2 peptides toward Category 1, pending a formal Federal Register notice (HHS, 2026). Until that notice publishes, ipamorelin stays where it is.
The Halftime POV
We follow the rules as written, not as we wish them. Ipamorelin is Category 2 right now, so it is not something a compliant pharmacy compounds today. If the status formally changes, the access conversation changes with it. Until then, we say so plainly.
Related reading:
- Why Some Peptides Are Still Category 2
- The April 2026 FDA Reclassification Path
- The Three-Category Access Model
- Sermorelin Regulatory Status
FAQ
Is ipamorelin legal? Ipamorelin is not a controlled substance, but its compounding access is restricted. The FDA classifies it as Category 2, so 503A pharmacies cannot legally compound it while that status stands. It is not banned as a molecule; it is not currently compoundable.
Is ipamorelin FDA approved? No. Ipamorelin is not FDA-approved for any use, and no compounded version is FDA-approved. It has been studied as a growth hormone secretagogue, but it has not gone through FDA approval as a marketed medicine.
Can you still get ipamorelin from a compounding pharmacy? Not from a compliant 503A pharmacy while it remains Category 2. A February 2026 HHS announcement proposed returning several Category 2 peptides toward Category 1, but that requires a formal Federal Register notice first.
What does Category 2 mean for ipamorelin? Category 2 means the FDA flagged safety questions about compounding it from bulk powder. In practice, licensed 503A pharmacies should not compound ipamorelin until its status changes.
Disclaimer
As of mid-2026, several peptides discussed in this article — including ipamorelin — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.
Get updates
Sources
- FDA, Human Drug Compounding Q&A: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
- FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-nominated-use-compounding-under-section-503a-fdca
- HHS, News and Announcements, 2026: https://www.hhs.gov/about/news/index.html
Frequently asked questions
Is ipamorelin legal?
Ipamorelin is not a controlled substance, but its compounding access is restricted. The FDA classifies it as a Category 2 bulk substance, which means 503A compounding pharmacies cannot legally compound it while that status stands. It is not banned as a molecule; it is not currently compoundable.
Is ipamorelin FDA approved?
No. Ipamorelin is not an FDA-approved drug for any use, and no compounded version is FDA-approved. It has been studied as a growth hormone secretagogue in research settings, but it has not gone through FDA approval as a marketed medicine.
Can you still get ipamorelin from a compounding pharmacy?
Not from a compliant 503A pharmacy while ipamorelin remains Category 2. A February 2026 HHS announcement proposed returning several Category 2 peptides toward Category 1, but that change requires a formal FDA Federal Register notice before access could resume.
What does Category 2 mean for ipamorelin?
Category 2 means the FDA has flagged significant safety questions about compounding the substance from bulk powder. In practice, it means licensed 503A pharmacies should not compound ipamorelin until its status changes.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.